Cargando…

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study

BACKGROUND: Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant. OBJECTIVE: The objective of this study was to evaluate patient sati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferguson, Gary T, Ghafouri, Mo, Dai, Luyan, Dunn, Leonard J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607534/ https://www.ncbi.nlm.nih.gov/pubmed/23658479 http://dx.doi.org/10.2147/COPD.S38577

Ejemplares similares

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial
por: Donohue, James F., et al.
Publicado: (2016)

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
por: MacGregor, TR, et al.
Publicado: (2016)

Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease
por: Panos, Ralph J
Publicado: (2013)

The Effect of Ipratropium Bromide with Violet Flower Extract, Ipratropium Bromide with Budesonide, and Ipratropium Bromide Alone on the Cuff-Leak of the Endotracheal Tube in Intubated ICU Patients
por: Hashemi, Seyed Taghi, et al.
Publicado: (2023)

Bromangiomas-ipratropium bromide–associated angiomas
por: Samlaska, Curt, et al.
Publicado: (2019)

Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions
por: Kamin, Wolfgang, et al.
Publicado: (2007)

Rare causes of anisocoria: Ipratropium bromide and Angel’s trumpet
por: Ekici, Arzu, et al.
Publicado: (2021)

Ipratropium bromide is more effective than Salmeterol — Fluticason combination on O(2) saturation patients with COPD
por: Rezaie, Nader, et al.
Publicado: (2013)

Transient anisocoria in a patient treated with nebulized ipratropium bromide
por: Pejic, Renato, et al.
Publicado: (2017)

Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD
por: Bhattacharya, Amal, et al.
Publicado: (2016)

Unilateral mydriasis secondary to ipratropium bromide in a critically ill patient
por: Santana-Cabrera, Luciano, et al.
Publicado: (2012)

Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling
por: Zhang, Jisheng, et al.
Publicado: (2023)

Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD
por: De Backer, LA, et al.
Publicado: (2011)

Effects of ipratropium bromide on the occurrence of postoperative respiratory complications in craniectomy patients with COPD: A nationwide multicenter retrospective study
por: Du, Zhuoying, et al.
Publicado: (2020)

Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis
por: Xu, Hongzhen, et al.
Publicado: (2021)

Efficacy and safety of olodaterol once daily delivered via Respimat(®) in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
por: Ferguson, Gary T, et al.
Publicado: (2014)

Use of inhaled ipratropium bromide to improve exercise-induced laryngeal obstruction cannot be recommended
por: Muralitharan, Praveen, et al.
Publicado: (2023)

Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease
por: Li, Xuan, et al.
Publicado: (2017)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Nebulized Ipratropium bromide protects against tracheal and bronchial secretion during bronchoscopy: A randomized controlled trial
por: Wang, Faping, et al.
Publicado: (2019)

Comparison of nebulised 3% hypertonic saline with ipratropium bromide in treatment of children with bronchiolitis: a randomized control trial
por: Naveed, Hina, et al.
Publicado: (2023)

Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
por: Haney, Sarah, et al.
Publicado: (2007)

Compatible Stability and Aerosol Characteristics of Atrovent(®) (Ipratropium Bromide) Mixed with Salbutamol Sulfate, Terbutaline Sulfate, Budesonide, and Acetylcysteine
por: Chen, Yiting, et al.
Publicado: (2020)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Unilateral pupillary mydriasis from nebulized ipratropium bromide: A false sign of brain herniation in the intensive care unit
por: Chaudhry, Priyanka, et al.
Publicado: (2014)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Bronchodilator Effect of Tiotropium via Respimat(Ⓡ) Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Ogasawara, Takashi, et al.
Publicado: (2017)

Effects of Ipratropium Bromide Combined with Traditional Chinese Medicine Intervention on the Pulmonary Function and Psychological Status of Patients with Chronic Obstructive Pulmonary Disease
por: Ye, Wen-Yi, et al.
Publicado: (2023)

Ipratropium Bromide/Salbutamol-Induced Acute Urinary Retention as a Result of Medication Error: A Case Report and Review of Cases in the Literature
por: Kubas, Mohammed Abdullah, et al.
Publicado: (2023)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Aerosol Characteristics and Physico-Chemical Compatibility of Combivent(®) (Containing Salbutamol and Ipratropium Bromide) Mixed with Three Other Inhalants: Budesonide, Beclomethasone or N-Acetylcysteine
por: Zhang, Rui, et al.
Publicado: (2020)

Compound Ipratropium Bromide plus Budesonide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Effect on Heparin-Binding Protein
por: Dong, Yuan, et al.
Publicado: (2022)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Comparison of Nebulized Epinephrine to Albuterol in Bronchiolitis
por: Walsh, Paul, et al.
Publicado: (2008)

Significant Lactic Acidosis from Albuterol
por: Hockstein, Maxwell, et al.
Publicado: (2018)

Subcutaneous terbutaline as an alternative to aerosolized albuterol
por: Strauss, Ronald A.
Publicado: (2020)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Airway hygiene in the ICU: can ipratropium plus salbutamol help?
por: Magalhaes, N
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_amhho9oeciq1hufco78nfve6ta